Federal contract award
W81K0022P0237
QUANTIDEX QPCR BCR ABL IS KIT REAGENTS AND QUANTIDEX QPCR BCR-ABL MINOR KIT REAGENTS.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Defense |
| Office | W40M MRC0 WEST |
| NAICS | 325413 — In-Vitro Diagnostic Substance Manufacturing |
| PSC | 6515 — Medical and Surgical Instruments, Equipment, and Supplies |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $552.5K |
| Current contract value | $737.9K |
| Potential contract value / ceiling | $737.9K |
| Start date | Oct 1, 2022 |
| Current end date | Sep 30, 2027 |
| Potential end date | Sep 30, 2027 |
| Latest award activity | Apr 17, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 13 of 13 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Apr 17, 2026 | P00012 | $0 | THE PURPOSE FOR THIS MODIFICATION IS TO DE-OBLIGATE EXCESS FY23 AND FY25 FUNDS, IN ORDER TO REFLECT ACTUAL AMOUNTS USED DURING PERFORMANCE OF THE CONTRACT IN FY23 (01 OCTOBER 2022 - 30 SEPTEMBER 2023) AND FY25 (1 OCTOBER 2024 - 30 SEPTEMBER 2025) |
| Dec 5, 2025 | P00011 | $-100.9K | THE PURPOSE FOR THIS MODIFICATION IS TO DE-OBLIGATE EXCESS FY23 AND FY25 FUNDS, IN ORDER TO REFLECT ACTUAL AMOUNTS USED DURING PERFORMANCE OF THE CONTRACT IN FY23 (01 OCTOBER 2022 - 30 SEPTEMBER 2023) AND FY25 (1 OCTOBER 2024 - 30 SEPTEMBER 2025) |
| Nov 25, 2025 | P00010 | $178.3K | BCR-ABL1, MAJOR (P210), QUANTITATIVE AND BCR-ABL1, MINOR (P190), QUANTITATIVE REAGENTS FOR BCR- ABL TESTING FOR BROOKE ARMY MEDICAL CENTER |
| Jul 18, 2025 | P00009 | $-2.4K | BCR-ABL1, MAJOR (P210), QUANTITATIVE AND BCR-ABL1, MINOR (P190), QUANTITATIVE REAGENTS FOR BCR- ABL TESTING FOR BROOKE ARMY MEDICAL CENTER |
| Apr 22, 2025 | P00008 | $0 | QUANTIDEX QPCR BCR ABL IS KIT |
| Nov 21, 2024 | P00007 | $171.5K | QUANTIDEX QPCR BCR ABL IS KIT - FUNDING MODIFICATION |
| Apr 26, 2024 | P00006 | $0 | QUANTIDEX QPCR BCR ABL IS KIT - EXERCISE THE FY25 OPTION YEAR. |
| Dec 18, 2023 | P00005 | $180.9K | QUANTIDEX QPCR BCR-ABL MINOR KIT (RUO)- FUNDING AND SHIPPING MODIFICATION. |
| Sep 19, 2023 | P00004 | $72.6K | QUANTIDEX QPCR BCR-ABL MINOR KIT (RUO) - MODIFICATION TO FUND CLINS 0003, 0004 AND 0005. |
| Aug 7, 2023 | P00003 | $0 | QUANTIDEX QPCR BCR-ABL MINOR KIT (RUO) - EXERCISE FY24 OPTION YEAR |
| Jul 21, 2023 | P00002 | $-105.1K | QUANTIDEX QPCR BCR-ABL MINOR KIT (RUO) - QUANTITY REDUCTION & PRICE INCREASE FOR BASE YEAR. |
| Nov 2, 2022 | P00001 | $157.6K | QUANTIDEX QPCR BCR ABL IS KIT -FY23 FUNDING |
| Sep 8, 2022 | 0 | $0 | QUANTIDEX QPCR BCR ABL IS KIT REAGENTS AND QUANTIDEX QPCR BCR-ABL MINOR KIT REAGENTS. |
Estimated positioning window
Oct 25, 2026 – Mar 30, 2027
80/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 80/100. Available recorded signals: 75 points.
- Contract end 2027-09-30 (340 days from calculation)
- +35 points
- 17 historical awards in this buyer and category group
- +15 points
- 13 recorded award transactions
- +10 points
- Latest award action: 2026-04-17
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.